202 related articles for article (PubMed ID: 35426442)
21. Novel IL36RN mutation in a Japanese case of early onset generalized pustular psoriasis.
Kanazawa N; Nakamura T; Mikita N; Furukawa F
J Dermatol; 2013 Sep; 40(9):749-51. PubMed ID: 23834760
[TBL] [Abstract][Full Text] [Related]
22. Increased neutrophil-derived IL-17A identified in generalized pustular psoriasis.
Lan Y; Wu X; Zhong X; Song P; Liu L; Liu Y; Ai X; Han C; Zhang Z
Exp Dermatol; 2024 Feb; 33(2):e15026. PubMed ID: 38414093
[TBL] [Abstract][Full Text] [Related]
23. The genetic background of generalized pustular psoriasis: IL36RN mutations and CARD14 gain-of-function variants.
Sugiura K
J Dermatol Sci; 2014 Jun; 74(3):187-92. PubMed ID: 24656634
[TBL] [Abstract][Full Text] [Related]
24. Correlation of IL36RN mutation with different clinical features of pustular psoriasis in Chinese patients.
Wang TS; Chiu HY; Hong JB; Chan CC; Lin SJ; Tsai TF
Arch Dermatol Res; 2016 Jan; 308(1):55-63. PubMed ID: 26589685
[TBL] [Abstract][Full Text] [Related]
25. Clinical characteristics of Japanese pustular psoriasis: A multicenter observational study.
Ohata C; Tsuruta N; Yonekura K; Higashi Y; Saito K; Katayama E; Imafuku S;
J Dermatol; 2022 Jan; 49(1):142-150. PubMed ID: 34723399
[TBL] [Abstract][Full Text] [Related]
26. The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist.
Sugiura K; Takemoto A; Yamaguchi M; Takahashi H; Shoda Y; Mitsuma T; Tsuda K; Nishida E; Togawa Y; Nakajima K; Sakakibara A; Kawachi S; Shimizu M; Ito Y; Takeichi T; Kono M; Ogawa Y; Muro Y; Ishida-Yamamoto A; Sano S; Matsue H; Morita A; Mizutani H; Iizuka H; Muto M; Akiyama M
J Invest Dermatol; 2013 Nov; 133(11):2514-2521. PubMed ID: 23698098
[TBL] [Abstract][Full Text] [Related]
27. A viewpoint on the genetic determinants of generalised pustular psoriasis.
Capon F
Exp Dermatol; 2023 Aug; 32(8):1188-1193. PubMed ID: 36645252
[TBL] [Abstract][Full Text] [Related]
28. Loss of Function
Kantaputra P; Daroontum T; Chuamanochan M; Chaowattanapanit S; Intachai W; Olsen B; Sastraruji T; Tongsima S; Ngamphiw C; Kampuansai J; Cox TC; Kiratikanon S
Genes (Basel); 2022 Dec; 14(1):. PubMed ID: 36672844
[TBL] [Abstract][Full Text] [Related]
29. [Remission of recalcitrant generalized pustular psoriasis under interleukin-36 receptor inhibitor spesolimab].
Müller VL; Kreuter A
Dermatologie (Heidelb); 2023 May; 74(5):356-359. PubMed ID: 36943426
[TBL] [Abstract][Full Text] [Related]
30. Clinical advances in biological therapy for generalized pustular psoriasis: a review.
Hsieh CY; Tsai TF
Expert Opin Biol Ther; 2024; 24(1-2):37-50. PubMed ID: 38247394
[TBL] [Abstract][Full Text] [Related]
31. Spesolimab, A Novel Interleukin-36 Inhibitor for Generalized Pustular Psoriasis Flares in Adult Patients.
Bukhari T; Markovina M; Abduelmula A; Rankin BD; Vender R; Yeung J; Devani AR; Prajapati VH
Skin Therapy Lett; 2024 Jan; 29(1):1-4. PubMed ID: 38271532
[TBL] [Abstract][Full Text] [Related]
32. Gastrointestinal bleeding with severe mucosal involvement in a patient with generalized pustular psoriasis without IL36RN mutation.
Komatsuda S; Kamata M; Chijiwa C; Namiki K; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Abe K; Yamamoto T; Aozasa N; Sugiura K; Tada Y
J Dermatol; 2019 Jan; 46(1):73-75. PubMed ID: 30474867
[TBL] [Abstract][Full Text] [Related]
33. Successful treatment with interleukin-17A antagonists of generalized pustular psoriasis in patients without IL36RN mutations.
Wilsmann-Theis D; Schnell LM; Ralser-Isselstein V; Bieber T; Schön MP; Hüffmeier U; Mössner R
J Dermatol; 2018 Jul; 45(7):850-854. PubMed ID: 29655177
[TBL] [Abstract][Full Text] [Related]
34. Lack of association between mutation in IL36RN and palmoplantar pustular psoriasis in Chinese patients.
Xiaoling Y; Dan S; Hongzhong J
An Bras Dermatol; 2019; 94(6):658-663. PubMed ID: 31789248
[TBL] [Abstract][Full Text] [Related]
35. A homozygous loss-of-function variant in the MPO gene is associated with generalized pustular psoriasis.
Onitsuka M; Farooq M; Iqbal MN; Yasuno S; Shimomura Y
J Dermatol; 2023 May; 50(5):664-671. PubMed ID: 36585391
[TBL] [Abstract][Full Text] [Related]
36. Genetics of Generalized Pustular Psoriasis: Current Understanding and Implications for Future Therapeutics.
Yang SF; Lin MH; Chou PC; Hu SK; Shih SY; Yu HS; Yu S
Genes (Basel); 2023 Jun; 14(6):. PubMed ID: 37372477
[TBL] [Abstract][Full Text] [Related]
37. Successful treatment of refractory juvenile generalized pustular psoriasis with secukinumab monotherapy: A case report and review of published work.
Ho PH; Tsai TF
J Dermatol; 2018 Nov; 45(11):1353-1356. PubMed ID: 30230584
[TBL] [Abstract][Full Text] [Related]
38. Granulocyte and monocyte apheresis can control juvenile generalized pustular psoriasis with mutation of IL36RN.
Koike Y; Okubo M; Kiyohara T; Fukuchi R; Sato Y; Kuwatsuka S; Takeichi T; Akiyama M; Sugiura K; Utani A
Br J Dermatol; 2017 Dec; 177(6):1732-1736. PubMed ID: 28369922
[TBL] [Abstract][Full Text] [Related]
39. Generalized Pustular Psoriasis: A Review of the Pathophysiology, Clinical Manifestations, Diagnosis, and Treatment.
Reynolds KA; Pithadia DJ; Lee EB; Clarey D; Liao W; Wu JJ
Cutis; 2022 Aug; 110(2 Suppl):19-25. PubMed ID: 36219603
[TBL] [Abstract][Full Text] [Related]
40. A review of disease burden and clinical management for generalized pustular psoriasis in China.
Lu J; Shi Y
Expert Rev Clin Immunol; 2022 Oct; 18(10):1023-1032. PubMed ID: 36040447
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
